ArticleFrontiers in immunology2026
The evaluation of the plasma levels of interleukin 17A, thymic stromal lymphopoietin, interferon gamma, tumor necrosis factor-alpha and interleukins IL-2, IL-6, IL-23, and IL-31 in atopic dermatitis patients with dupilumab treatment.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cytokine-Family Biomarker Candidates for Small Abdominal Aortic Aneurysm Identified via Integrated mRNA and Protein Expression Profiling.International journal of molecular sciences · 2026Article
- The evaluation of cytokine profiles in atopic dermatitis patients treated with dupilumab: association with ocular complications.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interleukin -17 (IL-17), particularly IL-17A, thymic stromal lymphopoietin (TSLP), interferon gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), IL-2, IL-6, IL-23, and IL-31 play a significant role in the pathogenesis of various chronic inflammatory and autoimmune skin diseases. Method: We conducted an assessment of plasma levels of interleukins IL-17A, TSLP, IFN-γ TNF-α, IL-2, IL-6, IL-23, and IL-31 in 89 atopic dermatitis (AD) patients and in 34 healthy individuals as a control group. The group of AD patients consisted of 27 patients treated with dupilumab for moderate and severe form (15 men, 12 women, mean age of 44.8 years) and 62 AD patients suffering from moderate and severe form without any systemic treatment (35 women,27 men, mean age of 46.3 years). The control group consisted of 34 healthy subjects (22 men, 12 women, mean age of 43.3 years). For screening analysis of plasma levels of cytokines the performance assay Human cytokine Luminex was used. Blood samples were unstimulated and stimulated with phorbol myristate acetate and ionomycin. The levels of IL-17A, TSLP, IFN-γ, TNF-α, IL-2, IL-6, IL-23, and IL-31 were compared in AD patients with the results in control group. Nonparametric Kruskal-Wallis analysis of variance with Results: Under unstimulated conditions we found these significant differences:1) Higher IL-17A and TNF-α in dupilumab-treated AD patients vs. healthy controls, suggesting residual Th17 and pro-inflammatory activity despite Th2 blockade. 2) TSLP elevated in both groups of AD patients indicating persistent epithelial barrier stress. 3) Low IFN-γ in both groups of AD patients is consistent with Th2 dominance. Under stimulated conditions we found these significant differences: 1) Lower IL-23 in both groups of AD patients vs. healthy controls suggesting possible impaired Th17 axis activation. 2) Lower IL-2 in patients without systemic treatment vs. healthy controls indicating reduced T-cell activation capacity without biologic therapy. 3) Higher IL-6 in both groups of AD patients vs. healthy controls reflecting ongoing innate/inflammatory activation under both conditions. Conclusion: Dupilumab effectively suppresses Th2 signaling but does not fully normalize immune balance
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.